Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Recruiting now · Phase 1
Conditions studied: EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
In brief
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Key facts
- Study ID
- NCT07315113
- Run by
- Nuvectis Pharma, Inc.
- People needed
- 18
- Starts
- 2025-12-18
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provide written informed consent.
- 18 years old or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
- Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
You may not qualify if…
- Subject's cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib
- Known human epidermal growth factor receptor 2 (HER2) overexpression
- Any contraindications to treatment with osimertinib
Where it is running
- Maryland Oncology Hematology — Calverton, Maryland, United States (enrolling)
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon, United States (enrolling)
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
- NEXT Houston — Houston, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.